Enterprise Value

156.4M

Cash

136.7M

Avg Qtr Burn

-6.187M

Short % of Float

1.56%

Insider Ownership

9.39%

Institutional Own.

14.64%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
UCART20x22 Details
Cancer, Non-Hodgkin lymphoma

Phase 1/2

Update

UCART22 Details
Acute lymphoblastic leukemia, Rare genetic disease, Cancer, B-cell acute lymphoblastic leukemia

Phase 1/2

Update

UCART123 Details
Relapsed/refractory acute myeloid leukemia, Cancer

Phase 1

Data readout

ALLO-501 Details
Non-Hodgkin lymphoma, Cancer

Failed

Discontinued

ALLO-715 Details
Cancer, Multiple myeloma

Failed

Discontinued

UCARTCS1 Details
Cancer, Multiple myeloma, Menkes Disease

Failed

Discontinued

UCART19 (anti-CD19) Details
Cancer, Multiple myeloma, Acute lymphoblastic leukemia

Failed

Discontinued